High Prevalence of Diabetes in Patients With Primary Aldosteronism (PA) Associated With Subclinical Hypercortisolism and Prediabetes More Prevalent in Bilateral Than Unilateral PA: A Large, Multicenter Cohort Study in Japan
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the prevalence and causes of diabetes in patients with primary aldosteronism (PA) in a multi-institutional cohort study in Japan. RESEARCH DESIGN AND METHODS: The prevalence of diabetes was determined in 2,210 patients with PA (diagnosed or glycated hemoglobin [HbA1c] ≥6.5% [≥48 mmol/mol]; NGSP) and compared with that of the Japanese general population according to age and sex. In 1,386 patients with PA and clear laterality (unilateral or bilateral), the effects of plasma aldosterone concentration (PAC), hypokalemia (<3.5 mEq/L), suspected subclinical hypercortisolism (SH; serum cortisol ≥1.8 µg/dL after 1-mg dexamethasone suppression test), and PA laterality on the prevalence of diabetes or prediabetes (5.7% ≤ HbA1c <6.5% [39 mmol/mol ≤ HbA1c <48 mmol/mol]) were examined. RESULTS: Of the 2,210 patients with PA, 477 (21.6%) had diabetes. This prevalence is higher than that in the general population (12.1%) or in 10-year cohorts aged 30–69 years. Logistic regression or χ2 test revealed a significant contribution of suspected SH to diabetes. Despite more active PA profiles (e.g., higher PAC and lower potassium concentrations) in unilateral than bilateral PA, BMI and HbA1c values were significantly higher in bilateral PA. PA laterality had no effect on the prevalence of diabetes; however, the prevalence of prediabetes was significantly higher in bilateral than unilateral PA. CONCLUSIONS: Individuals with PA have a high prevalence of diabetes, which is associated mainly with SH. The prevalence of prediabetes is greater for bilateral than unilateral PA, suggesting a unique metabolic cause of bilateral PA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 4×
“This study was presented in poster form at ENDO 2019, the Endocrine Society’s Annual Meeting, New Orleans, LA, 23–26 March 2019.”
BackgroundInfluentialReport of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus
The Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus, Seino, Y., Nanjo, K., Tajima, N., Kadowaki, T., Kashiwagi, A., Araki, E., Ito, C., Inagaki, N., Iwamoto, Y., et al. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00074.x · Cited by 1,772
Self-citationFassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014)
(2014) · Hypertension Research · doi:10.1038/hr.2014.20 · Cited by 1,049
Role for adrenal venous sampling in primary aldosteronism
Young, W. F., Stanson, A. W., Thompson, G. B., Grant, C. S., Farley, D. R., & van Heerden, J. A. (2004) · Surgery · doi:10.1016/j.surg.2004.06.051 · Cited by 735
Nishikawa, T., Omura, M., Satoh, F., Shibata, H., Takahashi, K., Tamura, N., & Tanabe, A. (2011) · Endocrine Journal · doi:10.1507/endocrj.ej11-0133 · Cited by 534
Self-citationThiazide Diuretics, Potassium, and the Development of Diabetes: A Quantitative Review
Zillich, A. J., Garg, J., Basu, S., Bakris, G. L., & Carter, B. L. (2006) · Hypertension · doi:10.1161/01.hyp.0000231552.10054.aa · Cited by 456
Human adipocytes secrete mineralocorticoid-releasing factors
Ehrhart-Bornstein, M., Lamounier-Zepter, V., Schraven, A., Langenbach, J., Willenberg, H. S., Barthel, A., Hauner, H., McCann, S. M., Scherbaum, W. A., & Bornstein, S. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336140100 · Cited by 443 · cited 2×
“factors, namely the older age and higher BMI and triglycerides in patients with bilateral PA, as has also been suggested by previous researchers (36,37).”
BackgroundResultClinical characteristics of primary aldosteronism from an analysis of 145 cases
Conn, J. W., Knopf, R. F., & Nesbit, R. M. (1964) · The American Journal of Surgery · doi:10.1016/0002-9610(64)90252-1 · Cited by 429 · cited 1×
“the basis of the above strict definitions, 505 patients with unilateral and 881 with bilateral PA (1,386) were ultimately included in the determination of effect of laterality on glucose intolerance.”
Background
Cited by
Naruse, M., Katabami, T., Shibata, H., Sone, M., Takahashi, K., Tanabe, A., Izawa, S., Ichijo, T., Otsuki, M., Omura, M., et al. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0508 · Cited by 217
“Aldosterone and cortisol cosecreting adenomas have several clinical characteristics, including larger size (>20 mm) and higher rates of glu‐ cose intolerance, osteoporosis, proteinuria, and cardio‐ vascular events compared with aldosterone-producing adenomas [21, 25, 71-74].”
BackgroundSelf-citationPrimary Aldosteronism: State-of-the-Art Review
Vaidya, A., Hundemer, G. L., Nanba, K., Parksook, W. W., & Brown, J. M. (2022) · American Journal of Hypertension · doi:10.1093/ajh/hpac079 · Cited by 150
Ohya, Y., Arakawa, K., Arata, N., Arima, S., Arima, H., Asayama, K., Dohi, Y., Fukami, A., Furuhashi, M., Goto, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-025-02462-y · Cited by 107
Self-citationPrimary aldosteronism decreases insulin secretion and increases insulin clearance in humans
Adler, G. K., Murray, G. R., Turcu, A. F., Nian, H., Yu, C., Solorzano, C. C., Manning, R., Peng, D., & Luther, J. M. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.13922 · Cited by 71
Hypokalemia in Diabetes Mellitus Setting
Coregliano-Ring, L., Goia-Nishide, K., & Rangel, É. B. (2022) · Medicina · doi:10.3390/medicina58030431 · Cited by 82
“Among individuals with primary hyperaldosteronism, there is evidence that the prevalence of DM is close to 21%, higher than an estimated 12% prevalence of DM in the general population [27].”
BackgroundAldosterone and Aldosterone Modulation in Cardio-Kidney Diseases
Fioretti, F., Testani, J. M., Tio, M. C., Pitt, B., & Butler, J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.012 · Cited by 56
Alteration of Gut Microbiota Relates to Metabolic Disorders in Primary Aldosteronism Patients
Liu, Y., Jiang, Q., Liu, Z., Shen, S., Ai, J., Zhu, Y., & Zhou, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.667951 · Cited by 47
“DM and obesity are more common in PA patients than in healthy people or primary hypertension patients (2, 3).”
BackgroundTargeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension
Erlic, Z., Reel, P. S., Reel, S., Amar, L., Pecori, A., Larsen, C. K., Tetti, M., Pamporaki, C., Prehn, C. P., Adamski, J., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa954 · Cited by 47
Prevalence, diagnosis and outcomes of treatment for primary aldosteronism
Yang, Y., Reincke, M., & Williams, T. A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101365 · Cited by 43
Molecular and Epigenetic Control of Aldosterone Synthase, CYP11B2 and 11-Hydroxylase, CYP11B1
Takeda, Y., Demura, M., Kometani, M., Karashima, S., Yoneda, T., & Takeda, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065782 · Cited by 42
“Autonomous cortisol secretion in PA also contributes to metabolic risk or cardiovascular complications [94,95].”
BackgroundSelf-citationTakeda, Y., Demura, M., Yoneda, T., & Takeda, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094587 · Cited by 38
Self-citationConstantinescu, G. A., Langton, K., Conrad, C., Amar, L., Assié, G., Gimenez‐Roqueplo, A., Blanchard, A., Larsen, C. K., Mulatero, P., Williams, T. A., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa423 · Cited by 33
Outcomes in unilateral primary aldosteronism after surgical or medical therapy
Puar, T. H. K., Loh, L. M., Loh, W. J., Lim, D. S. T., Zhang, M., Tan, P. T., Lee, L. M. Y., Swee, D. S., Khoo, J. J. C., Tay, D., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14351 · Cited by 33
Epigenetic Regulation of the Renin–Angiotensin–Aldosterone System in Hypertension
Takeda, Y., Demura, M., Yoneda, T., & Takeda, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158099 · Cited by 35
“Increased prevalences of diabetes mellitus and metabolic syndrome in patients with PA were reported in a large cohort study [45,46].”
BackgroundSelf-citationSecondary diabetes mellitus due to primary aldosteronism
Moustaki, M., Paschou, S. Α., Vakali, E., & Vryonidou, A. (2022) · Endocrine · doi:10.1007/s12020-022-03168-8 · Cited by 30
Kobayashi, Y., Haze, T., Yano, Y., Tamura, K., Kurihara, I., Ichijo, T., Yoneda, T., Katabami, T., Tsuiki, M., Wada, N., et al. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.06.012 · Cited by 29
“Study Design and Patients This study was conducted as a part of the prospective ongoing JPAS/JRAS project, a nationwide PA registry of patients from 22 universities and 19 city hospitals.(7,10,11) Both JPAS and JRAS enrolled patients with PA 20 to 90 years of age between January 2006 and January 2019.”
MethodSelf-citationIon homeostasis in diabetic kidney disease
Hu, H., Liang, W., & Ding, G. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.09.009 · Cited by 30
Billmann, F. G., Billeter, A. T., Thomusch, O., Keck, T., Shishtawi, S. E., Langan, E. A., Strobel, O., & Müller-Stich, B. P. (2020) · Surgery · doi:10.1016/j.surg.2020.09.005 · Cited by 28
Inoue, K., Kitamoto, T., Tsurutani, Y., Saito, J., Omura, M., & Nishikawa, T. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645488 · Cited by 28
Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea
Yoon, M., Hong, N., Ha, J., Lee, C. J., Ku, C. R., Rhee, Y., & Park, S. (2022) · Hypertension Research · doi:10.1038/s41440-022-00948-7 · Cited by 24
“Moreover, patients with PA have a high prevalence of diabetes and obesity [38, 39].”
BackgroundSpyroglou, A., Handgriff, L., Müller, L., Schwarzlmueller, P., Parasiliti‐Caprino, M., Fuß, C. T., Remde, H., Hirsch, A., O’Toole, S. M., Thuzar, M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0040 · Cited by 22
Self-citationThe Entity of Connshing Syndrome: Primary Aldosteronism with Autonomous Cortisol Secretion
Carşote, M. (2022) · Diagnostics · doi:10.3390/diagnostics12112772 · Cited by 27
Clinical characterization of patients with primary aldosteronism plus subclinical Cushing’s syndrome
Yasuda, S., Hikima, Y., Kabeya, Y., Iida, S., Oikawa, Y., Isshiki, M., Inoue, I., Shimada, A., & Noda, M. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0490-0 · Cited by 22
Liu, Y., Zhou, L., Liu, Z., Ma, Y., Lin, L., Zhu, Y., Wang, K., & Li, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00023 · Cited by 27
A Bibliometric Analysis of Primary Aldosteronism Research From 2000 to 2020
Wang, C., Jing, H., Sun, Z., Yao, J., Zhang, X., Liu, T., & Wu, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.665912 · Cited by 20
“PA patients have an increased risk of stroke, heart failure, coronary artery disease, atrial fibrillation (1, 3–5), renal damage (6, 7), diabetes (8, 9), metabolic syndrome (9, 10).”
BackgroundBenefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism
Ahmed, S., & Hundemer, G. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.861581 · Cited by 22
Castro, M. A., Ruiz-Sánchez, J. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Aguilera-Saborido, A., Cerezo, J. F. G., Lazareno, N. L., Quesada, M. E. T., Ramos, J. G., Oriola, J., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03751-1 · Cited by 25
“…atrial fi brillation) [24, 55, 56], HT [57, 58], insulin resistance [59], albuminuria [58] and other complex mechanisms related to metabolic diseases [60] such as obstructive sleep apnea [61 – 63], obesity [64 – 66], diabetes mellitus [8, 67 – 69] and alterations of calcium metabolism [70].”
Effects of Primary Aldosteronism and Different Therapeutic Modalities on Glucose Metabolism
Kwak, M. K., Lee, J. Y., Kim, B., Lee, S. H., & Koh, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122194 · Cited by 19
“Although recent studies showed that higher prevalence of DM in PA patients might be associated mainly with SH [27,28], our result showed PA patients without SH, and thus with aldosterone excess alone, had a higher prevalence of DM than do sex-, age-, and BMI-matched controls.”
BackgroundResultLoh, H. H., & Sukor, N. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-019-0294-8 · Cited by 21
Okazaki‐Hada, M., Moriya, A., Nagao, M., Oikawa, S., Fukuda, I., & Sugihara, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13312 · Cited by 20
Zhang, Z., Luo, Q., Tuersun, T., Wang, G., Wu, T., Zhang, D., Wang, M., Zhou, K., Sun, L., Yue, N., et al. (2020) · Clinical Endocrinology · doi:10.1111/cen.14318 · Cited by 17
Adrenal Venous Sampling for Subtype Diagnosis of Primary Hyperaldosteronism
Naruse, M., Tanabe, A., Yamamoto, K. I., Rakugi, H., Kometani, M., Yoneda, T., Kobayashi, H. H., Abe, M., Ohno, Y., Inagaki, N., et al. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1192 · Cited by 22
Self-citationManagement of primary aldosteronism and mineralocorticoid receptor-associated hypertension
Morimoto, S., & Ichihara, A. (2020) · Hypertension Research · doi:10.1038/s41440-020-0468-3 · Cited by 18
Temporal trends in clinical features of patients with primary aldosteronism over 20 years
Park, S. S., Ahn, C. H., Kim, S. W., Koh, J., Lee, S. H., & Kim, J. H. (2024) · Hypertension Research · doi:10.1038/s41440-024-01703-w · Cited by 17
“Patients with PA are at a higher risk for cardiovascular diseases, atrial fi brillation, stroke, type 2 diabetes, metabolic syndrome, and mortality than those with essential hypertension [4 – 7].”
BackgroundSaiki, A., Otsuki, M., Tamada, D., Kitamura, T., Shimomura, I., Kurihara, I., Ichijo, T., Takeda, Y., Katabami, T., Tsuiki, M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa177 · Cited by 17
Self-citationWu, W.-C., Peng, K., Lu, J., Chan, C., Wang, C., Tseng, F., Yang, W., Lin, Y., Lin, P., Chen, T.-C., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0286 · Cited by 14
Zhang, S.-L., Gao, J., Guo, Y., Feng, Q., Tang, J., Yan, L., Wang, J., Cheng, H., & Liu, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.547356 · Cited by 15
Subtype-specific Body Composition and Metabolic Risk in Patients With Primary Aldosteronism
Park, S. S., Ahn, C. H., Kim, S. W., Yoon, J. W., & Kim, J. H. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad520 · Cited by 14
Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism
Nakamaru, R., Yamamoto, K. I., Akasaka, H., Rakugi, H., Kurihara, I., Yoneda, T., Ichijo, T., Katabami, T., Tsuiki, M., Wada, N., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.16449 · Cited by 15
Self-citationImpact of primary aldosteronism on renal function in patients with type 2 diabetes
Katsuragawa, S., Tsurutani, Y., Takiguchi, T., Saito, J., & Nishikawa, T. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13332 · Cited by 13
Primary Hyperaldosteronism: When to Suspect It and How to Confirm Its Diagnosis
Ruiz-Sánchez, J. G., Pazos, M., Meneses, D., & Rünkle, I. (2022) · Endocrines · doi:10.3390/endocrines3010003 · Cited by 11
Yazdanpanah, M., Delaney, S. R., & Beriault, D. R. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad065 · Cited by 11
The value of plasma metanephrine measurements during adrenal vein sampling
Carroll, R. W., Corley, B., Feltham, J., Whitfield, P., Park, W., Howard, R., Yssel, M., Phillips, I., Harper, S., & Yang, J. (2023) · Endocrine Connections · doi:10.1530/ec-23-0300 · Cited by 14
“Of particular relevance to patients with primary aldosteronism, the prevalence of cortisol co-secretion is high at between 13 and 33% (19, 20, 21, 22, 23).”
BackgroundHamidi, O., Shah, M., Zhang, C. D., Lazik, N., Li, D., Singh, S., Iñiguez‐Ariza, N. M., Raman, R., Hurtado, M. D., Carafone, L. E., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae078 · Cited by 12
Ruiz-Sánchez, J. G., Sánchez, Á. F., Cárdenas‐Salas, J., Fernández-Cagigao, Y., Bellassai, E. R. A., Rossello, G., Fernández‐Fernández, B., Moreno, B. J., Paniagua, A., Vázquez, C., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003822 · Cited by 11
Risk Factors Associated With Lower Bone Mineral Density in Primary Aldosteronism Patients
Lv, X., Hu, H., Shen, C., Zhang, X., Yan, L., Zhang, S., & Guo, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.884302 · Cited by 11
Teragawa, H., Oshita, C., Orita, Y., Hashimoto, K., Nakayama, H., Yamazaki, Y., & Sasano, H. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i5.1119 · Cited by 12
Ruiz-Sánchez, J. G., Sánchez, Á. F., & Meneses, D. (2024) · Endocrine · doi:10.1007/s12020-024-03798-0 · Cited by 9
“PA itself entails a higher cardiovascular risk, and is strongly associated with other cardiovascular risk factors such as obesity [4 – 7], obstructive sleep apnea (OSA) [8 – 10], chronic kidney disease (CKD) [11, 12], metabolic syndrome, and type 2 diabetes (T2D) [13 – 16].”
Wei, X., Wu, F., Dong, H., Jing, Y., Song, Y., Pang, H., Chen, J., Du, Z., He, W., Ma, L., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03865-6 · Cited by 11
Kubo, H., Tsurutani, Y., Inoue, K., Watanabe, K., Yamazaki, Y., Sunouchi, T., Hoshino, Y., Hirose, R., Katsuragawa, S., Tannai, H., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267732 · Cited by 10
“Additionally, a higher frequency of DM in the unsuppressed PRA group also might be derived from subclinical hypercortisolism [44].”
BackgroundWu, V., Chan, C., Wu, W.-C., Peng, K., Chang, Y.-S., Yeh, F.-Y., Chiang, J., Lee, Y., Liu, K., Wang, S., et al. (2022) · Hypertension Research · doi:10.1038/s41440-022-01086-w · Cited by 10
“In concordance with previous reports [3, 37, 38], we also found no significant difference in the incidence of NODM between those with different subtypes of PA (e.”
BackgroundResultInfluentialThe role of confirmatory tests in the diagnosis of primary aldosteronism
Huang, C., Tu, K., Fan, K., Tsai, C., Wang, W., Wang, S., Wu, C.-Y., Hu, Y.-H., Huang, S.-H., Liu, H.-W., et al. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.04.022 · Cited by 9
Then, C., Ritzel, K., Herder, C., Then, H. L., Sujana, C., Heier, M., Meisinger, C., Peters, A., Köenig, W., Rathmann, W., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002558 · Cited by 9
“In one study, dietary sodium restriction resulted in a decreased insulin sensitivity in participants with type 2 diabetes, 42 whereas in another study including non-diabetic participants, sodium restriction did not affect insulin sensitivity but impaired insulin secretion.”
ResultMogi, M., Tanaka, A., Node, K., Tomitani, N., Hoshide, S., Narita, K., Nozato, Y., Katsurada, K., Maruhashi, T., Higashi, Y., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01398-5 · Cited by 9
Self-citationAdrenalectomy for primary aldosteronism and its related surgical characteristics
Xiang, H., Zhang, T., Song, W., Yang, D., & Zhu, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1416287 · Cited by 8
Metabolic phenotypes and fatty acid profiles associated with histopathology of primary aldosteronism
Yang, Y., Liu, Y., Williams, T. A., Gao, M., Yan, Y., Bao, M., Tao, J., Ma, G., Wang, M., Xia, Z., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02143-w · Cited by 8
Zhu, Q., & Zhu, F. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14607 · Cited by 7
Li, N., Lin, M., Heizhati, M., Wang, L., Luo, Q., Li, Y., Yili, J., Hong, J., Yao, X., & Zhu, Q. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038694 · Cited by 7
A novel clinical-imaging nomogram for predicting primary aldosteronism in patients with hypertension
Liu, Y., Wang, M., Qiu, X., Ma, G., Ji, M., Yang, Y., & Sun, M. (2023) · Hypertension Research · doi:10.1038/s41440-023-01374-z · Cited by 6
“The mean blood glucose, insulin sensitivity and incidence of diabetes were signi fi cantly higher in PA patients than in EH patients [23, 24].”
BackgroundZhao, L., Wan, J., Wang, Y., Yang, W., Liang, Q., Wang, J., & Jin, P. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1068335 · Cited by 5
Predictive model for persistent hypertension after surgical intervention of primary aldosteronism
Li, Z., He, Y., Zhang, Y., Chen, G., Zheng, Y., Guo, Y., Quan, Z., & Wu, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-39028-2 · Cited by 5
Bu, X., Sun, F., Zhang, H., Liu, X., Zhao, Z., He, H., Li, Y., Yan, Z., & Zhu, Z. (2022) · Journal of Diabetes Research · doi:10.1155/2022/8932133 · Cited by 6
“Recently, a multicenter cohort study reported that prediabetes is more prevalent in bilateral PA than in unilateral PA [16].”
BackgroundPan, L.-H., Chen, Y.-Y., Pan, C., Hsu, C., Tseng, C., Yen, I., Chan, C., & Lin, L. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.08.010 · Cited by 7
Siboto, A., Akinnuga, A. M., Ismail, M. B., Booysen, I. N., Sibiya, N. H., Ngubane, P. S., & Khathi, A. (2022) · Diabetology · doi:10.3390/diabetology3040040 · Cited by 6
“GLUT 2 transports glucose independently of insulin, and this results in a higher rate of hepatic glycogenesis occurring due to the shunting of glucose during the prediabetic state [46].”
BackgroundRecovery from diabetes mellitus in primary aldosteronism patients after adrenalectomy
Liu, Y., Lin, L., Yuan, C., Shen, S., Tang, Y., Liu, Z., Zhu, Y., & Zhou, L. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01254-6 · Cited by 8
Barrea, L., Caprio, M., Perrini, S., Camajani, E., Crafa, A., Gangitano, E., Gorini, S., Sciacca, L., Verde, L., Albertelli, M., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02589-2 · Cited by 5
“Among them, there are hormones that play a role in the counterregulatory response to insulin, such as glucagon, catecholamines, cortisol, and growth hormone (GH) [ 3 ].”
Liu, L., Li, X., Ma, W., Fan, F., Yang, Y., Zhang, L., Yi, T., Zhang, J., Guo, J., & Gao, Y. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02594-5 · Cited by 4
Zhang, C., Jiang, Y., Su, T., Jiang, L., Zhou, W., Zhong, X., Wu, L., & Wang, W. (2022) · Endocrine · doi:10.1007/s12020-022-03095-8 · Cited by 4
Gao, H., Li, L., & Tian, H. (2022) · Medicine · doi:10.1097/md.0000000000030008 · Cited by 4
“Despite these diagnostic challenges, patients with A/ CPA are indeed more prone to metabolic abnormalities[13] and present a higher risk of cardiovascular events,[14] a phenomenon that is worthy of attention in the medical community.”
BackgroundSakaguchi, S., Okamoto, R., Inoue, C., Akao, M., Kamemura, K., Kurihara, I., Takeda, Y., Ohno, Y., Inagaki, N., Rakugi, H., et al. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-022-00753-2 · Cited by 4
Self-citationYokota, K., & Sone, M. (2023) · Hypertension Research · doi:10.1038/s41440-022-01149-y · Cited by 4
“also showed a higher DM prevalence in patients with PA than in the general population [4].”
BackgroundSelf-citationImpaired Glucose Tolerance in Primary Aldosteronism: Mechanism(s) and Clinical Implications
Kotchen, T. A. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14765 · Cited by 4
Gao, H., Li, L., Chen, F., Ren, Y., Chen, T., & Tian, H. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01454-8 · Cited by 3
“…cardio-vascular and cerebrovascular events would increase [4]; (3) glucose intolerance and other metabolic complications would be aggravated [5, 6]; (4) patients would be prone towards osteoporosis [7, 8]; (5) adrenal vein sampling results may be misinterpreted [9]; and (6) adrenal…”
BackgroundHigh prevalence of primary aldosteronism in a tertiary care hospital in Lebanon
Jambart, I., Kassab, R., Gannagé‐Yared, M., Kassab, R., Naim, C., & Ghorayeb, N. E. (2025) · Medicine · doi:10.1097/md.0000000000041384 · Cited by 4
Sanyal, D., Mukhopadhyay, P., & Ghosh, S. K. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i18.3332 · Cited by 2
Chu, W.-K., Er, L., Chang, C., Lu, J., Wu, W.-C., Tsai, Y., Lin, Y., & Wu, V. (2024) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223241301892 · Cited by 2
Aldosterone & cortisol cosecretion
Candela, P., Figueredo, C., & Hanzu, F. A. (2025) · Vitamins and hormones · doi:10.1016/bs.vh.2025.10.009 · Cited by 2
Takeda, Y., Demura, M., Kometani, M., Karashima, S., Aono, D., Konishi, S., Horike, S., Meguro‐Horike, M., Yoneda, T., & Takeda, Y. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej23-0103 · Cited by 2
Self-citationIkemoto, M., Morimoto, S., & Ichihara, A. (2024) · Hypertension Research · doi:10.1038/s41440-024-01651-5 · Cited by 2
Morimoto, S., & Ichihara, A. (2022) · Hypertension Research · doi:10.1038/s41440-022-00979-0 · Cited by 2
“Patients with PA are at a higher risk of cardiovascular and cerebrovascular events, heart [2, 3] and renal diseases [2, 4], diabetes mellitus, metabolic syndrome [2, 5], and reduced quality of life [6, 7] than patients with essential hypertension.”
BackgroundChen, D., Li, Y., Wu, J., Lin, W., Zhong, L., Feng, P., & Gan, W. (2024) · Laboratory Medicine · doi:10.1093/labmed/lmae065 · Cited by 1
Grasselli, C., Baldini, M., Salvi, L., Vestita, G., Zizzo, M., Felaco, D., Balli, M. C., Besutti, G., Negro, A., & Ghirarduzzi, A. (2025) · Diseases · doi:10.3390/diseases13020052 · Cited by 1
“Therefore, further studies are needed to confirm these results.”
Diabete e sindrome metabolica nel paziente con iperaldosteronismo primario
Bernardi, S., Velardi, V., Luca, F. D., Zuolo, G., Calabrò, V., Candido, R., & Fabris, B. (2024) · L Endocrinologo · doi:10.1007/s40619-023-01410-7 · Cited by 1
“Tale co-secrezione sembra interessare dal 74 al 77% dei pazienti con iperaldosteronismo e in questi pazienti sem-bra essere uno dei meccanismi alla base dell’aumentata pre-valenza di DMT2 e di alterazioni metaboliche [6, 18].”
InfluentialOhira, M., Abe, K., Yamaguchi, T., Onda, H., Yamaoka, S., Nakamura, S., Tanaka, S., Watanabe, Y., Nabekura, T., Oshiro, T., et al. (2022) · Obesity Facts · doi:10.1159/000521855
Hillson, R. (2022) · Practical Diabetes · doi:10.1002/pdi.2372
Chu, W.-K., Wang, C., Wu, W.-C., & Wu, V. (2023) · Research Square · doi:10.21203/rs.3.rs-2658889/v1
liu, W., Zhou, J., Yi, S., Shen, M., Li, Z., & Su, X. (2024) · Research Square · doi:10.21203/rs.3.rs-3939206/v1
Liu, Y., Lin, L., Chi, Y., Shen, S., Tang, Y., Liu, Z., Zhu, Y., & Zhou, L. (2023) · Figshare · doi:10.6084/m9.figshare.22601660
Yanase, T. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej20231005
Self-citationPrimary aldosteronism: Diagnosis and treatment
Parksook, W. W., & Vaidya, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00135-7
Clinical Significance of Skeletal Fat‐to‐Muscle Ratio in Idiopathic Hyperaldosteronism
Jiang, Y., Li, D. X., Cao, C. C., Feng, W., Liu, R., Xu, Y., & Cao, C. (2025) · Clinical Endocrinology · doi:10.1111/cen.15274
“It is known that the prevalence of obesity and diabetes is higher in IHA than in APA, and insulin resistance (IR) is a leading cause of glucose intolerance in IHA [18].”
Glucocorticoids: The culprit behind metabolic disorders in primary Aldosteronism? A narrative review
Kmieć, P., & Świątkowska−Stodulska, R. (2025) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2025.100401
“…2019 Japanese study, although DM was more prevalent in PA patients than in the general population, the difference was driven mainly by suspected subclinical hypercortisolemia (currently mild autonomous cortisol secretion, MACS) on the basis of the overnight 1-mg DXM suppression test (DST) [32].”
InfluentialChu, W.-K., He, J., Peng, Y.-B., Fu, H.-W., Wu, V., & Yuan, H. (2025) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/14703203251347397
Ye, L., Wu, Y., Wei, H., Liang, X., Lin, J., Huang, S., Mo, Z., & Li, M. (2026) · Endocrine · doi:10.1007/s12020-026-04571-1
Jiang, Y., Zhang, X., Zeng, Q., Zhang, A., Du, Z., Song, Y., Hu, J., Ma, L., Yang, Y., He, Y. F., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004319
Zaidi, N. E., Azizan, E. A. B. A., & Ali, A. (2026) · Biomedicines · doi:10.3390/biomedicines14102321
“…multicohort study of 2210 patients, diabetes prevalence was significantly higher in bilateral than unilateral PA and was independently associated with concurrent subclinical hypercortisolism, implicating both aldosterone excess and glucocorticoid co-secretion as additive diabetogenic signals [193].”
Metadata
- Authors
- Akehi, Y., Yanase, T., Motonaga, R., Umakoshi, H., Tsuiki, M., Takeda, Y., Yoneda, T., Kurihara, I., Itoh, H., Katabami, T., Ichijo, T., Wada, N., Shibayama, Y., Yoshimoto, T., Ashida, K., Ogawa, Y., Kawashima, J., Sone, M., Inagaki, N., Takahashi, K., Fujita, M., Watanabe, M., Matsuda, Y., Kobayashi, H., Shibata, H., Kamemura, K., Otsuki, M., Fujii, Y., Yamamoto, K., Ogo, A., Okamura, S., Miyauchi, S., Fukuoka, T., Izawa, S., Hashimoto, S., Yamada, M., Yoshikawa, Y., Kai, T., Suzuki, T., Kawamura, T., & Naruse, M.
- Affiliations
- Fukuoka University (JP)
- Kyoto Medical Center (JP)
- Kanazawa University (JP)
- Keio University (JP)
- St. Marianna University School of Medicine (JP)
- Department of Endocrinology and Metabolism, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan
- Sapporo City General Hospital (JP)
- Tokyo Medical and Dental University (JP)
- Kyushu University (JP)
- Kumamoto University (JP)
- Kyoto University (JP)
- Showa General Hospital (JP)
- The University of Tokyo (JP)
- Okazaki City Hospital (JP)
- Sanda City Hospital (JP)
- Nihon University (JP)
- Oita University (JP)
- Shinko Hospital (JP)
- The University of Osaka (JP)
- Medical Corporation JR Hiroshima Hospital (JP)
- National Kyushu Medical Center (JP)
- Tenri Hospital (JP)
- Uwajima City Hospital (JP)
- Matsuyama Red Cross Hospital (JP)
- Tottori University Hospital (JP)
- Fukushima Medical University Hospital (JP)
- Gunma University (JP)
- Department of Endocrinology and Diabetes Mellitus, Misato Kenwa Hospital, Misato, Japan
- Saiseikai Tondabayashi Hospital (JP)
- International University of Health and Welfare (JP)
- Corresponding author
- Yanase, Toshihiko
- ORCID
- Yanase, Toshihiko
- Umakoshi, Hironobu
- Tsuiki, Mika
- Takeda, Yoshiyu
- Yoneda, Takashi
- Kurihara, Isao
- Itoh, Hiroshi
- Katabami, Takuyuki
- Ichijo, Takamasa
- Wada, Norio
- Yoshimoto, Takanobu
- Ashida, Kenji
- Ogawa, Yoshihiro
- Kawashima, Junji
- Sone, Masakatsu
- Inagaki, Nobuya
- Fujita, Megumi
- Watanabe, Minemori
- Kobayashi, Hiroki
- Shibata, Hirotaka
- Otsuki, Michio
- Fujii, Yuichi
- Yamamoto, Koichi
- Okamura, Shintaro
- Miyauchi, Shozo
- Izawa, Shoichiro
- Yamada, Masanobu
- Kai, Tatsuya
- Suzuki, Tomoko
- Kawamura, Takashi
- Naruse, Mitsuhide
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-03-27
- Volume
- 42
- Issue
- 5
- Pages
- 938-945
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2939049266
- Cited by
- 95
- References
- 38
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 16 · 2023: 15 · 2022: 24 · 2021: 6 · 2020: 17 · 2019: 3
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (18H01654)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Nephrology › Potassium and Related Disorders
- Keywords
- primary aldosteronism, diabetes prevalence, prediabetes, subclinical hypercortisolism, bilateral primary aldosteronism, unilateral primary aldosteronism, aldosterone, hypokalemia, dexamethasone suppression test, HbA1c
- MeSH terms
- Adult, Aged, Aged, 80 and over, Aldosterone, Cushing Syndrome, Diabetes Mellitus, Female, Glycated Hemoglobin, Humans, Hyperaldosteronism, Japan, Male, Middle Aged, Prediabetic State, Retrospective Studies, Cohort Studies, Prevalence, Diabetes Complications, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.